Image source: Shutterstock

Highlights

  • ImpediMed's SOZO-Core business revenue increased by 14% in FY24.
  • In FY24, total revenue dropped by 9% due to the cessation of the AstraZeneca trial.
  • The company aims to reduce cash expenditure by 10% in FY25.

ImpediMed Limited (ASX:IPD) is an ASX-listed medical software technology company that utilises bioimpedance spectroscopy (BIS) for non-invasive measurement and monitoring of fluid status and tissue composition. On 8 October 2024, the company notified that the US National Accreditation Program for Breast Centres has updated its standards to include BIS.

IPD is the only company that provides FDA-cleared BIS technology for clinically assessing lymphoedema. The SOZO technology of IPD is well recognised and accepted for its accuracy and effectiveness in screening for lymphoedema.

During the financial year 2024 (FY24), revenue from SOZO-Core business increased by 14% YoY to AUD 9.7 million, while total revenue dropped by 9% YoY to AUD 10.3 million. Group revenue fell in FY24 due to cessation of the AstraZeneca trial.

The period also recorded fall in operating loss before tax to AUD 19.8 million from AUD 20.5 million. During the reported period, the company conducted restructuring, cost cutting and reallocation of resources to customer-facing roles.

IPD Outlook

The focus is on supporting clinicians in achieving top-tier guideline-driven care to prevent breast care-related lymphoedema (BCRL), establishing SOZO as a vital investment in patient outcomes.

Moreover, the company is committed to boosting sales and improving cost efficiency. In FY25, cash expenditure anticipated to decrease 10% compared to FY24.  

In 1HFY25, the company plans to participate in 14 conferences in the US to increase awareness of SOZO among a broader range of stakeholders involved in BCRP prevention.

Share performance of IPD

IPD shares closed 1.69% lower at AUD 0.058 apiece on 9 October 2024. In the past one year, IPD’s share price has declined by almost 61.33%, while, in the past one month, it has increased by 26.09%.

52-week high of IPD is AUD 0.16, recorded on 10 January 2024, and 52-week low is AUD 0.042, recorded on 11 September 2024.

IPD Daily Technical Chart, Source: REFINITIV

Note 1: Past performance is neither an Indicator nor a guarantee of future performance.

Note 2: The reference date for all price data, and currency, is 09 October 2024. The reference data in this report has been partly sourced from REFINITIV.